PDCD1 and posterior cortical atrophy: Sena et al. [93] recently demonstrated that tumour frameshift mutation proportion offered more robust neo-antigenic peptides that were targeted by anti-PD1 antibody pembrolizumab leading to a better clinical response in dMMR PCa patients [93].